Alphatec Holdings Reports Strong 2025 Preliminary Results, Positive 2026 Outlook, and Secures Key Biologic Distribution Rights
ATEC has more than doubled off its 52-week low of $8.81.
Summary
Alphatec Holdings announced robust preliminary 2025 financial results with 25% revenue growth and provided an optimistic 2026 outlook, projecting 17% revenue growth and increased profitability. The company also secured exclusive U.S. distribution rights for OsteoAdapt, a next-generation rhBMP-2 biologic.
Key Events · Earnings and Guidance · ATEC
-
Strong 2025 Preliminary Financial Results
Reported approximately $764 million in total revenue for full-year 2025, representing 25% growth, and re-affirmed adjusted EBITDA guidance of $91 million.
-
Positive 2026 Financial Outlook
Projected full-year 2026 total revenue of $890 million (17% growth), adjusted EBITDA of $130 million, and $20 million in free cash flow.
-
Acquisition of Exclusive Biologic Distribution Rights
Secured exclusive U.S. distribution rights for Theradaptive's OsteoAdapt®, a next-generation rhBMP-2 solution in Phase II clinical trials, enhancing future procedural offerings.
Analysis · ATEC · Industrial Applications And Services
Alphatec Holdings' 8-K filing reveals strong operational momentum, highlighted by preliminary 2025 revenue growth of 25% to approximately $764 million and a re-affirmed adjusted EBITDA guidance of $91 million. The company's 2026 outlook is equally positive, forecasting total revenue of $890 million (17% growth) and a significant increase in adjusted EBITDA to $130 million, alongside an expected $20 million in free cash flow. This financial performance indicates continued surgeon adoption and effective leverage of its scalable infrastructure. Furthermore, the acquisition of exclusive U.S. distribution rights for OsteoAdapt, a next-generation rhBMP-2 solution in Phase II clinical trials, is a strategic move to expand its procedural offerings and address market concentration in biologics, positioning the company for sustained long-term growth. Investors should view these updates as a strong signal of the company's execution and future potential in the spine market.
At the time of this filing, ATEC was trading at $21.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $8.81 to $23.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.